Skip to search formSkip to main contentSkip to account menu

OPC 28326

Known as: OPC-28326 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Aniline CompoundsPiperidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
OPC-28326, a Selective Peripheral Vasodilator with Angiogenic Action, Attenuates Postinfarction Cardiac Remodeling
2007
2007
OPC-28326, a selective femoral arterial vasodilator, augments ischemia induced angiogenesis.
2005
2005
Neurogenic double-peaked vasoconstriction of human gastroepiploic artery is mediated by both alpha1- and alpha2-adrenoceptors.
1. The contribution of postjunctional P2X receptors and subtypes of alpha-adrenoceptors to vasoconstrictor responses following… 
Review
2004
Review
2004
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2003
2003
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2002
2002
Effect of oral OPC-28326, a selective femoral arterial vasodilator, on hindlimb subcutaneous tissue temperature in conscious dogs under buprenorphine sedation.
In dogs, rectal temperature was decreased to about 36 degrees C at 2 to 2.5 h after sedation with buprenorphine (0.3 mg/body, i.m… 
2001
2001
α2‐adrenoceptor antagonist properties of OPC‐28326, a novel selective peripheral vasodilator
Antagonistic properties of OPC‐28326 ([4‐(N‐methyl‐2‐phenylethylamino)‐1‐(3,5‐dimethyl‐4‐propionyl‐aminobenzoyl)] piperidine… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)